My research focuses on induction of protection immunity, typically focusing on mucosal immunity, infection, and adjuvants. My lab uses bacterial ADP-ribosylating enterotoxins derived from E. coli for the manipulation of protective immunity, including the novel adjuvants dmLT and LTA1. In addition, I am interested in host factors and biomarkers of protective immunity, including for dmLT-adjuvanted clinical trials, influenza vaccination, and now SARS-CoV-2 infection